Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22461412 | 0.94 | KDM4E (0.67) | KDM4ESMN1; SMN2GAATDP1AOC3 | |
| SCHEMBL2297276 | 0.91 | BCHE (0.63) | KDM4ESMN1; SMN2GAATDP1LMNA | |
| SCHEMBL2295136 | 0.91 | BCHE (0.63) | KDM4ESMN1; SMN2GAATDP1LMNA | |
| SCHEMBL7649318 | 0.86 | MEN1 (0.63) | KDM4ESMN1; SMN2TDP1LMNAMEN1 | |
| SCHEMBL2297389 | 0.85 | MITF (0.63) | KDM4ESMN1; SMN2GAATDP1AOC3 | |
| SCHEMBL2293496 | 0.85 | MITF (0.63) | KDM4ESMN1; SMN2GAATDP1AOC3 | |
| SCHEMBL2296911 | 0.85 | ADRB3 (0.56) | KDM4ESMN1; SMN2GAATDP1AOC3 | |
| SCHEMBL2296487 | 0.85 | ADRB3 (0.56) | KDM4ESMN1; SMN2GAATDP1AOC3 | |
| SCHEMBL2295329 | 0.85 | ADRB3 (0.56) | KDM4ESMN1; SMN2GAATDP1AOC3 | |
| SCHEMBL9672979 | 0.85 | MEN1 (0.67) | KDM4ESMN1; SMN2GAATDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2004-09-30 | — | — | US | disclosed |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2003-11-27 | — | — | US | disclosed |
| US-6608203-B2 | Devoid of unwanted side effects | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | CAMERON KIMBERLY O (US) | 2001-11-08 | — | — | US | disclosed |
| EP-1113007-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | PFIZER INC. (US) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039285-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | KDM4E 1201/4885SMN1; SMN2 3840/4885GAA 3639/4885 |
| US-20030220494-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | KDM4E 1201/4885SMN1; SMN2 3840/4885GAA 3639/4885 |
| US-20040192685-A1 | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists | GPER1, ESR1, ESR2 | KDM4E 1201/4885SMN1; SMN2 3840/4885GAA 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.